Literature DB >> 33646329

Predictors and outcomes of ischemic stroke in reversible cerebral vasoconstriction syndrome.

Aayushi Garg1, Matthew Starr2, Marcelo Rocha2, Santiago Ortega-Gutierrez3.   

Abstract

INTRODUCTION: The clinical factors predisposing to ischemic stroke in reversible cerebral vasoconstriction syndrome (RCVS) are unclear. In this observational cross-sectional study, we aimed to evaluate the risk factors and clinical outcomes associated with the development of ischemic stroke in patients with RCVS.
METHODS: We utilized the Nationwide Readmissions Database 2016-2017 to identify all hospitalizations with RCVS, with or without acute ischemic stroke. Independent predictors of and clinical outcomes associated with ischemic stroke were analyzed using logistic regression.
RESULTS: Among 1065 hospitalizations for RCVS (mean ± SD age 49.0 ± 16.7 years, female 69.7%), 267 (25.1%) had ischemic stroke. Patients with ischemic stroke were more likely to have hypertension (OR 2.33, 95% CI 1.51-3.60), diabetes (OR 1.81, 95% CI 1.11-2.98), and tobacco use (OR 1.64, 95% CI 1.16-2.33) and were less likely to have a history of migraine (OR 0.56, 95% CI 0.35-0.90). Ischemic stroke was associated with higher odds of cerebral edema (OR 3.15, 95% CI 1.31-7.57) and respiratory failure (OR 2.39, 95% CI 1.28-4.44). Patients with ischemic stroke also had longer hospital stay by a mean duration of 6.7 days, P < 0.001, higher hospital charges by a mean of $72,961, P < 0.001, and a higher likelihood of not being discharged to home (OR 3.57, 95% CI 2.39-5.33). They had higher in-hospital mortality rate; however, the difference was not statistically significant.
CONCLUSION: Ischemic stroke affects nearly 25% of patients with RCVS and is associated with adverse clinical outcomes. RCVS patients with cerebrovascular risk factors might have a higher predisposition for developing ischemic lesions during the disease process.
© 2021. Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  Cerebral edema; Diabetes; Disposition; Hypertension; RCVS; Tobacco

Mesh:

Year:  2021        PMID: 33646329     DOI: 10.1007/s00415-021-10456-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  8 in total

1.  Predictors and outcomes of hemorrhagic stroke in reversible cerebral vasoconstriction syndrome.

Authors:  Aayushi Garg; Marcelo Rocha; Matthew Starr; Santiago Ortega-Gutierrez
Journal:  J Neurol Sci       Date:  2021-01-07       Impact factor: 3.181

2.  Hemorrhagic Reversible Cerebral Vasoconstriction Syndrome: Features and Mechanisms.

Authors:  Mehmet A Topcuoglu; Aneesh B Singhal
Journal:  Stroke       Date:  2016-06-07       Impact factor: 7.914

3.  Reversible cerebral vasoconstriction syndromes: analysis of 139 cases.

Authors:  Aneesh B Singhal; Rula A Hajj-Ali; Mehmet A Topcuoglu; Joshua Fok; James Bena; Donsheng Yang; Leonard H Calabrese
Journal:  Arch Neurol       Date:  2011-04-11

Review 4.  Reversible cerebral vasoconstriction syndrome.

Authors:  Anne Ducros
Journal:  Lancet Neurol       Date:  2012-10       Impact factor: 44.182

5.  Hemorrhagic manifestations of reversible cerebral vasoconstriction syndrome: frequency, features, and risk factors.

Authors:  Anne Ducros; Ursula Fiedler; Raphael Porcher; Monique Boukobza; Christian Stapf; Marie-Germaine Bousser
Journal:  Stroke       Date:  2010-09-30       Impact factor: 7.914

Review 6.  Reversible cerebral vasoconstriction syndrome.

Authors:  Anne Ducros; Marie-Germaine Bousser
Journal:  Pract Neurol       Date:  2009-10

7.  Clinical worsening in reversible cerebral vasoconstriction syndrome.

Authors:  Brian S Katz; Jennifer E Fugate; Sebastián F Ameriso; Virginia A Pujol-Lereis; Jay Mandrekar; Kelly D Flemming; David F Kallmes; Alejandro A Rabinstein
Journal:  JAMA Neurol       Date:  2014-01       Impact factor: 18.302

8.  The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients.

Authors:  Anne Ducros; Monique Boukobza; Raphaël Porcher; Mariana Sarov; Dominique Valade; Marie-Germaine Bousser
Journal:  Brain       Date:  2007-11-19       Impact factor: 13.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.